uniQure N.V. research snapshot
QURE AI stock analysis currently reads uniQure N.V. as a high-risk, high-reward gene therapy biotechnology company with an advancing regulatory catalyst. The analysis is not a certain price prediction. At the August 4, 2026 cutoff, the latest verified close used here was $44.06, market capitalization was about $3.06 billion, and the main question is whether the AMT-130 Huntington disease BLA submission planned for Q3 2026 stays on track for accelerated approval, with topline four-year data expected in September 2026. The company reported Q2 2026 revenue of $5.84 million on July 29, 2026, beating consensus, while the EPS loss of $1.22 missed estimates. Cash of $810.3 million at June 30, 2026 extends the runway into 2030. This is informational research and not investment advice.
Current price
$44.06
Market cap
$3.06 billion
AI score
52 / 100
Rating
High-risk pre-commercial gene therapy company with confirmed FDA alignment for an AMT-130 accelerated approval BLA
Trend status
Strong uptrend, +84% YTD and +222% over one year, consolidating near $44 after the Q2 2026 report
Data cutoff (updated monthly)
August 4, 2026
Informational use only. This page is not investment advice.
| Dimension | Conclusion | Confidence |
|---|---|---|
| Business quality | uniQure is a gene therapy platform company with one approved product (Hemgenix for hemophilia B) and a CNS and rare disease pipeline led by AMT-130 for Huntington disease. The model is capital-intensive with binary pipeline risk. | Medium |
| Moat | The moat comes from proprietary AAV vector manufacturing know-how, CNS delivery expertise, and first-mover regulatory experience in Huntington disease gene therapy. Competitive gene therapy programs from other companies could narrow this advantage over time. | Low-medium |
| Management | Management secured written FDA alignment that an accelerated approval BLA for AMT-130 is reasonable, kept the Q3 2026 submission on track, and raised about $259 million in a June 2026 offering that extends the cash runway into 2030. The Q2 EPS miss reflected higher SG&A and non-operating charges rather than pipeline failure. | Medium |
| Financial trend | TTM revenue reached about $18.67 million, but the company remains deeply unprofitable with a TTM net loss of about $252 million and levered free cash flow of about -$78 million. Cash of $810.3 million provides an unusually long runway for a biotech at this stage. | Medium |
| Valuation | Standard valuation metrics are not meaningful for this pre-profit biotech. At $44.06, the market cap of $3.06 billion implies a large pipeline premium, with price to sales near 146x and price to book near 9.4x. The cash-adjusted enterprise value of about $2.28 billion still assumes strong AMT-130 optionality. | Low |
| Technical trend | QURE is in a strong uptrend, up 84% YTD and 222% over one year, but well below its 52-week high of $71.50. Barchart technical opinion rated the stock at 88% Buy with the strongest short-term outlook. | Medium-high |
| Risk level | Key risks are AMT-130 regulatory or clinical setback, a confirmatory study design that the FDA wants aligned before filing, disappointing September four-year data, competitive gene therapy programs, and high volatility with implied volatility near 106%. | Medium-high |
| AI confidence | Medium confidence for business description, cash position, market pricing, and major risk categories. Lower confidence for future regulatory outcomes and pipeline valuation. | Medium data confidence |
| Investment certainty | Low certainty. uniQure is a high-risk biotech where the investment outcome depends heavily on AMT-130 approval, commercialization execution, and capital market conditions. | Low |
QURE AI stock forecast
The QURE AI stock forecast uses scenario ranges around the $44.06 cutoff price. It does not claim that AI can predict a specific future price. The bullish case requires the AMT-130 BLA to be accepted with FDA alignment on a confirmatory study and supportive September four-year data. The base case assumes the BLA proceeds through a standard review with questions. The bearish case assumes regulatory setbacks or disappointing data.
$65 to $100
More likely if the AMT-130 BLA is submitted in Q3 2026, the confirmatory study design aligns with FDA expectations, and the September 2026 four-year data remain supportive. Recent analyst targets from Wells Fargo ($75) and H.C. Wainwright ($80), with a high Street target near $96, frame this zone.
$40 to $65
More likely if the BLA is accepted but the review extends, the confirmatory study adds timeline risk, or the stock trades between technical support near $40 and the consensus target of about $68.
$20 to $38
More likely if the FDA requires a larger confirmatory study before filing, the September four-year data disappoint, or the approval timeline slips. The stock could fall toward cash-adjusted value if the pipeline thesis weakens.
QURE AI technical analysis
QURE AI technical analysis starts from the $44.06 close on August 3, 2026 used for this August 4 static page. The stock is in a strong medium-term uptrend, up 84% YTD and 222% over one year, but remains roughly 38% below its 52-week high of $71.50. Barchart rated the technical opinion at 88% Buy. Because this page does not fetch request-time market data, traders should confirm levels on a live chart before acting.
| Level | Value | Why it matters |
|---|---|---|
| Current price | $44.06 | Latest verified close used for this page, from August 3, 2026, the last trading day before the data cutoff. |
| Near support | $42.60 to $41.14 | First and second support levels per Barchart key turning points. Holding above $41.14 keeps the near-term uptrend intact. |
| Secondary support | $40.06 | Third support level per Barchart, close to the Fibonacci 50% retracement of $40.11. A break below would signal fading momentum. |
| Near resistance | $45.14 to $46.22 | First and second resistance zones per Barchart. Reclaiming $45.14 would suggest renewed buying interest. |
| Key resistance | $47.68 | Third resistance level, near the Fibonacci 61.8% retracement of $47.52. A close above would open the path toward the 52-week high area. |
| 52-week range | $8.73 to $71.50 | The stock has a wide 52-week range, reflecting its binary biotech nature. The current price sits roughly 38% below the high and far above the low. |
| Momentum | Strong over 1, 3, and 6 months | QURE gained about 5% in one month, 130% in three months, and 84% YTD as of August 3, 2026, with a 1-year gain near 222%. |
| Volume | About 1.06M shares on August 3 | Volume of 1.06M was below the 2.18M average, suggesting the recent consolidation lacks heavy distribution pressure. |
| Volatility | IV near 106%, HV near 60% | Implied volatility of 106.44% and historical volatility of 60.39% underscore the extreme price risk. The options market implied an expected move of about 7% over 18 days. |
| Invalidation | Close below $40.06, then $32.71 | A close below $40.06 (third support and near the Fibonacci 50% level) weakens the medium-term technical picture. A break below $32.71 (Fibonacci 38.2%) would challenge the bull thesis. |
QURE AI trading strategy
The QURE AI trading strategy is a rules-based framework, not personalized advice. It combines regulatory calendar evidence, technical confirmation, strict position sizing, and clear invalidation levels. Due to the extreme volatility and binary nature of biotech stocks, risk management is paramount.
Monitor for the AMT-130 BLA submission (expected Q3 2026), FDA confirmation of the confirmatory study design, and the September 2026 four-year data readout. Price tends to move sharply on regulatory and data news cycles.
Reduce position size before binary events. A negative September data readout, a delayed filing, or a clinical hold could cause a 40-60% drawdown.
If QURE holds $41 to $42.60 support without a fundamental thesis break, look for volume confirmation and technical stabilization before considering a position. The stock has traded above these levels since the June rally.
Biotech pullbacks can turn into structural declines. Never add to a position solely because the price dropped. Wait for regulatory or data confirmation.
Given implied volatility near 106% and a roughly 7% expected move over 18 days, position sizing should be a fraction of what would be used for lower-volatility stocks. Define maximum loss before entry.
Use the $40.06 invalidation level and the $44.06 current price to define an initial stop distance of about 9%. The extreme volatility means stops can be triggered by normal noise.
Investment research summary
uniQure develops one-time curative gene therapies for severe genetic diseases. Patients or their insurers pay for a single treatment that replaces or repairs a defective gene, creating a product revenue model with large per-patient pricing but slow, lumpy adoption.
The moat is proprietary AAV-based gene therapy manufacturing expertise, IP around CNS delivery, and first-mover regulatory experience. Hemgenix was the first FDA-approved gene therapy for hemophilia B, and commercial-scale AAV manufacturing know-how creates a barrier for competitors.
The thesis can fail if AMT-130 misses efficacy endpoints or shows safety issues in the ongoing Phase I/II study, if the FDA requires a large confirmatory study before accepting the BLA, if competitors develop better Huntington treatments, or if cash is burned faster than the runway suggests before commercial revenue arrives.
Management progressed AMT-130 to a confirmed accelerated approval pathway, reported positive early data from AMT-260 and AMT-191, and raised about $259 million in June 2026, extending the cash runway into 2030. The main execution question is whether the confirmatory study can be designed and started quickly enough to satisfy the FDA.
Gene therapy represents a long-term secular shift in medicine, moving from symptom management toward one-time curative treatments. CNS gene therapy for Huntington disease, epilepsy, and other unmet needs addresses large patient populations with few current treatment options.
At $44.06 and a $3.06 billion market cap, with $810 million in cash and TTM revenue of about $18.67 million, nearly all enterprise value is attributed to pipeline potential. The current price requires successful AMT-130 approval and commercial execution to be justified.
Source-backed data
Every metric below includes a source and last verification date.
| Metric | Value | Source | Last verified |
|---|---|---|---|
| QURE price | $44.06 close on August 3, 2026 | Yahoo Finance and StockAnalysis quote snapshots | August 4, 2026 |
| Market capitalization | $3.06B, verified as $44.06 x 69.37M shares with 0.01% deviation | financial_rigor.py market cap verification; Yahoo Finance 3.056B, StockAnalysis 3.06B, Barchart 3.026B, all within 1% | August 4, 2026 |
| 52-week range | $8.73 to $71.50 | Yahoo Finance and StockAnalysis | August 4, 2026 |
| TTM revenue | $18.67M | Yahoo Finance and StockAnalysis; cross-validation showed 0% deviation | August 4, 2026 |
| Q2 2026 results | Revenue $5.84M beat of $4.71M consensus; EPS loss of $1.22 missed $0.71 consensus | uniQure Q2 2026 press release via GlobeNewswire and Zacks | August 4, 2026 |
| TTM net income | -$252.21M | Yahoo Finance financial summary | August 4, 2026 |
| Cash and investments | $810.3M at June 30, 2026 | uniQure Q2 2026 press release; Yahoo Finance total cash (mrq) $810.33M, 0% deviation | August 4, 2026 |
| Public offering (June 2026) | $259M gross from 5,686,813 shares at $45.50, closed June 25, 2026 | uniQure press release via GlobeNewswire | August 4, 2026 |
| Analyst consensus | Strong Buy, average target about $68 to $69 | StockAnalysis $69.43 and Yahoo Finance $68.02, cross-validation within 1.03% | August 4, 2026 |
| Barchart technical opinion | 88% Buy (Strong Buy) | Barchart technical analysis overview | August 4, 2026 |
| P/E (TTM) | N/A (negative earnings) | Yahoo Finance statistics | August 4, 2026 |
This QURE AI stock analysis is an informational tool for research and education only. It is not investment advice, a recommendation, or a guarantee of future performance. Forecast ranges are scenarios based on available data as of August 4, 2026 and can be wrong. Biotech stocks carry elevated risk of total capital loss.
Design trading strategies visually with 10+ indicators. Set entry/exit conditions and risk management, then generate Pine Script code with no coding required.
Filter and discover stocks based on market cap, dividend yield, P/E ratio, sector, and more. Screen thousands of stocks with real-time data.
Smart AI-driven stock selection with fundamental screening, analyst estimates, and key metrics. Filter by P/E, market cap, dividends, and more.
